ArticleCase reports in immunology2026
Adult Onset of Acute Disseminated Encephalomyelitis (ADEM) With Associated Myelin Oligodendrocyte Glycoprotein (MOG) Antibody.
Article in Case reports in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adult Onset of Acute Disseminated Encephalomyelitis (ADEM) With Associated Myelin Oligodendrocyte Glycoprotein (MOG) Antibody.Case reports in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ADEM is an inflammatory and demyelinating autoimmune disorder of the central nervous system (CNS). One recognized cause of ADEM is myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD affects approximately one in 10,000 people worldwide and is more prevalent in children. Patients typically present with optic neuritis, ADEM, and transverse myelitis. Many patients will experience relapses of demyelinating attacks, and thus, both acute and maintenance therapies are typically used to manage the disease. This case considers an adult female who presented with neurological deficits as a result of MOG-associated ADEM. She had minimal response to traditional therapies but responded well to treatment with IV immunoglobulin (IVIG). This case report explores her clinical course as well as unique clinical significance and conclusions due to the nontraditional use of IVIG.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.